Bruce Carvalho
Papers
1
Total Citations
4
H-Index
1
About
Bruce Carvalho’s research career has centered on advancing drug development through innovative ADME/Tox screening technologies. His most notable contribution is the development and validation of three critical assays—Cytochrome P450 Inhibition, Serum Protein Binding, and P-glycoprotein Interaction—on Tecan’s LabCD-ADMET System, a microfluidic platform designed to streamline early-stage drug candidate evaluation. This work, detailed in his highly cited 2003 paper “ADMET Assays on Tecan’s LabCD-ADMET System,” demonstrated the system’s ability to efficiently and reliably assess key pharmacokinetic and toxicity properties, offering a faster, more integrated approach to compound screening. By enabling simultaneous evaluation of multiple ADME parameters, Carvalho’s research helped reduce bottlenecks in drug discovery pipelines, providing researchers with a powerful tool for identifying promising leads earlier. Though his publication record is focused, his impact is clear: his foundational work on miniaturized, automated ADMET assays continues to inform modern high-throughput screening strategies, making him a key figure in the evolution of preclinical drug safety assessment.
Research Focus
Key Achievements
Top Papers
- 1ADMET Assays on Tecan's LabCD-ADMET System4 citations · 2003